108 related articles for article (PubMed ID: 16731744)
1. Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin.
Olivero M; Ruggiero T; Saviozzi S; Rasola A; Coltella N; Crispi S; Di Cunto F; Calogero R; Di Renzo MF
Mol Cancer Ther; 2006 May; 5(5):1126-35. PubMed ID: 16731744
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
Bardella C; Dettori D; Olivero M; Coltella N; Mazzone M; Di Renzo MF
Clin Cancer Res; 2007 Apr; 13(7):2191-8. PubMed ID: 17404103
[TBL] [Abstract][Full Text] [Related]
3. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis.
Coltella N; Rasola A; Nano E; Bardella C; Fassetta M; Filigheddu N; Graziani A; Comoglio PM; Di Renzo MF
Int J Cancer; 2006 Jun; 118(12):2981-90. PubMed ID: 16395709
[TBL] [Abstract][Full Text] [Related]
4. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
5. The integrin-linked kinase-associated phosphatase (ILKAP) is a regulatory hub of ovarian cancer cell susceptibility to platinum drugs.
Lorenzato A; Torchiaro E; Olivero M; Di Renzo MF
Eur J Cancer; 2016 Jun; 60():59-68. PubMed ID: 27065457
[TBL] [Abstract][Full Text] [Related]
6. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
7. PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy.
Musiani D; Hammond DE; Cirillo L; Erriquez J; Olivero M; Clague MJ; Di Renzo MF
J Proteome Res; 2014 Nov; 13(11):4970-82. PubMed ID: 25099161
[TBL] [Abstract][Full Text] [Related]
8. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin.
Rasola A; Anguissola S; Ferrero N; Gramaglia D; Maffe A; Maggiora P; Comoglio PM; Di Renzo MF
Cancer Res; 2004 Mar; 64(5):1744-50. PubMed ID: 14996735
[TBL] [Abstract][Full Text] [Related]
10. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
11. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.
Brozovic A; Fritz G; Christmann M; Zisowsky J; Jaehde U; Osmak M; Kaina B
Int J Cancer; 2004 Dec; 112(6):974-85. PubMed ID: 15386344
[TBL] [Abstract][Full Text] [Related]
12. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.
Persons DL; Yazlovitskaya EM; Cui W; Pelling JC
Clin Cancer Res; 1999 May; 5(5):1007-14. PubMed ID: 10353733
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin induced apoptosis of ovarian cancer A2780s cells by activation of ERK/p53/PUMA signals.
Song H; Wei M; Liu W; Shen S; Li J; Wang L
Histol Histopathol; 2018 Jan; 33(1):73-79. PubMed ID: 28287251
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase.
Zhou HY; Pon YL; Wong AS
Endocrinology; 2007 Nov; 148(11):5195-208. PubMed ID: 17673518
[TBL] [Abstract][Full Text] [Related]
16. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
17. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.
Solár P; Sytkowski AJ
Cancer Lett; 2011 Oct; 309(1):11-8. PubMed ID: 21676537
[TBL] [Abstract][Full Text] [Related]
18. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
[TBL] [Abstract][Full Text] [Related]
19. Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells.
Kamazawa S; Kigawa J; Minagawa Y; Itamochi H; Shimada M; Takahashi M; Sato S; Akeshima R; Terakawa N
Oncology; 2000 Nov; 59(4):329-35. PubMed ID: 11096346
[TBL] [Abstract][Full Text] [Related]
20. HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor.
Pavan S; Musiani D; Torchiaro E; Migliardi G; Gai M; Di Cunto F; Erriquez J; Olivero M; Di Renzo MF
Int J Cancer; 2014 Mar; 134(6):1289-99. PubMed ID: 23996744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
